Show simple item record

dc.contributor.authorAnastassopoulou, C. G.en
dc.contributor.authorKostrikis, Leontios G.en
dc.date.accessioned2019-11-04T12:50:10Z
dc.date.available2019-11-04T12:50:10Z
dc.date.issued2003
dc.identifier.issn1570-162X
dc.identifier.urihttp://gnosis.library.ucy.ac.cy/handle/7/52916
dc.description.abstractHuman allelic variants influence the susceptibility to HIV-1 infection and/or the subsequent rates of disease progression towards AIDS that average ten years, although they vary greatly among infected subjects. In this respect, studies involving multiply exposed persons who remain uninfected, long-term nonprogressors (who remain asymptomatic for fifteen years or more) or, in contrast, rapid progressors (who develop AIDS within two to three years post-infection) as well as seroincident cohorts of patients with defined seroconversion dates have contributed to our comprehension of the effects of different natural human polymorphisms on HIV-1 disease. The current article aims at providing an up-to-date review on these polymorphisms that may be broadly classified into three general categories: (1) those that control viral entry into susceptible cells (namely, chemokine and chemokine receptor polymorphisms), (2) mutational variants of genes involved in immune regulation, such as interleukin-10 (IL-10), interleukin-4 (IL-4), tumor necrosis factor-alpha (TNF-alpha), and mannose-binding lectin (MBL), and (3) polymorphisms in genes involved in the adaptive immune recognition by T cells, [human leukocyte antigen (HLA) type]. Particular emphasis has been placed on the state-of-the-art biotechnological methodologies, such as "spectral genotyping" that utilizes molecular beacons in conjunction with polymerase chain reaction in real-time (real-time-PCR), which were developed to assist with the characterization of some of these determinants. Elucidating the functional role of these factors via the application of such biotechnological assays is expected to further enhance our understanding of the pathogenesis of HIV-1 infection, and, eventually, to enrich our therapeutic arsenal with novel antiviral agents or strategic approaches.en
dc.sourceCurr HIV Resen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-2142770398&partnerID=40&md5=a806032a6f14e1dcd62b91909e4f792c
dc.subjecthumanen
dc.subjectHumansen
dc.subjectDisease Progressionen
dc.subjectreviewen
dc.subjectHuman immunodeficiency virus infectionen
dc.subjectdisease courseen
dc.subjectalleleen
dc.subjectgenetic polymorphismen
dc.subjectGenetic Predisposition to Diseaseen
dc.subjectHIV Infectionsen
dc.subjectgenetic predispositionen
dc.subjectgeneticsen
dc.subjectAllelesen
dc.subjectHuman immunodeficiency virus 1en
dc.subjectHIV-1en
dc.subjectgenetic variabilityen
dc.subjectVariation (Genetics)en
dc.subjectPolymorphism, Geneticen
dc.titleThe impact of human allelic variation on HIV-1 disease.en
dc.typeinfo:eu-repo/semantics/article
dc.description.volume1
dc.description.startingpage185
dc.description.endingpage203
dc.type.uhtypeArticleen
dc.description.notes<p>Cited By :25</p>en
dc.source.abbreviationCurr HIV Resen
dc.contributor.orcidKostrikis, Leontios G. [0000-0002-5340-7109]


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record